Shots: The company has submitted the IND to the US FDA for evaluating its re-purposed drug NP-120 (Ifenprodil) in P-IIb/III study as a potential therapeutic treatment against COVID-19. The study […]readmore
Tags : IND
Shots: The approval follows the trials which involves assessing of HLX13 vs originator ipilimumab to evaluate its pharmacology, pharmacokinetics and toxicokinetics profiles, immunogenicity, and toxicity The study resulted in biosimilarity […]readmore
Shots: Following the IND approval, Celularity will initiate P-I/II study assessing CYNK-001 in 86 patients with COVID-19. The company deems CYNK-001 is the first FDA’s IND cleared immunotherapy to treat […]readmore
Shots: The NMPA has accepted the IND for HLX14, a biosimilar referencing Prolia, indicated for the treatment of postmenopausal women with osteoporosis at high risk for fracture HLX14 is developed […]readmore
Shots: Bio-Thera to initiate P-I study to evaluate the PK and safety study of BAT2206 (proposed biosimilar) vs Janssen’s Stelara (ustekinumab) US & EU-sourced in normal healthy candidates The clinical […]readmore
Shots: Mannin Research (a technology partner of Q Biomed) and Mcmaster University collaborated to research and develop drug delivery and formulation of MAN-01, to treat Glaucoma The focus of the […]readmore